Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

181.81 USD -2.68 (-1.45%)
Streaming Delayed Price Updated: 2:40 PM EDT, Apr 12, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
90 91 Next >
Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together
Eli Lilly and Company (NYSE: LLY) today announced changes to the purchase agreements with the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for... 
From PR Newswire
Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting
Confirmed Objective Response Rate of 47 Percent, with Responses Observed in Nine Unique Cancer Types 
From PR Newswire
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
- Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical... 
From PR Newswire
Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application... 
From PR Newswire
Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2021 financial results on Tuesday, April 27, 2021. Lilly will also conduct a conference call on that day with the investment community... 
From PR Newswire
Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts
Eli Lilly and Company (NYSE: LLY) will host a webcast for the investment community, media and the general public on May 4, 2021 to provide an overview of the company's strong commitment to... 
From PR Newswire
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
- More than 80 percent of HCPs wish they had the time to more closely track patients who are seeing multiple providers 
From PR Newswire
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
– In combination, the two monoclonal antibodies demonstrated a 70% relative reduction in persistently high viral load at day 7 compared to placebo – 
From GlobeNewswire News Releases
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
- In combination, the two monoclonal antibodies demonstrated a 70% relative reduction in persistently high viral load at day 7 compared to placebo - 
From PR Newswire
NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: ATNF) Developing Groundbreaking Anti-Inflammatory Therapeutics
From InvestorBrandNetwork
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk... 
From Business Wire News Releases
Controlling Inflammation to Stop Disease
From InvestorBrandNetwork
Controlling Inflammation to Stop Disease
NetworkNewsWire Editorial Coverage 
From PR Newswire
Psychedelics Becoming Valuable Alternatives to Conventional Mental Health Treatments
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Psychedelics Becoming Valuable Alternatives to Conventional Mental Health Treatments
A pressing need for new treatment options for people suffering from mental health issues has opened the door to a new era of mental health innovation. Researchers, regulators, and consumers are... 
From PR Newswire
Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021
PRO data further support the monarchE results to date for Verzenio for the treatment of HR+, HER2- high risk early breast cancer 
From PR Newswire
Thinking about trading options or stock in Alibaba, Moderna, Square, Exxon Mobil, or Eli Lilly?
InvestorsObserver issues critical PriceWatch Alerts for BABA, MRNA, SQ, XOM, and LLY. 
From PR Newswire
Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study
- Patients treated with mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints compared to placebo 
From PR Newswire
Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM
Findings from the primary endpoint supported by consistency of all secondary outcome measures assessing cognition and function 
From PR Newswire
Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)
Presentation of Phase 1/2 LIBRETTO-001 trial data will highlight safety and efficacy data of Retevmo® (selpercatinib) in the treatment of RET fusion-positive cancers outside of lung and thyroid cancer 
From PR Newswire
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
- New data show therapy reduced risk of hospitalizations and death by 87 percent 
From PR Newswire
Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research
Highlights include results from the Phase 2 Trailblazer-ALZ study for donanemab 
From PR Newswire
Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations
Edgardo Hernandez named Senior Vice President, President of Manufacturing Operations 
From PR Newswire
Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes
Biolojic is eligible to receive up to $121 million, consisting of potential milestones and a promissory note, as well as tiered royalties 
From PR Newswire
Lilly to Participate in Barclays Global Healthcare Conference
Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 9, 2021. Patrik Jonsson, senior vice president, president of Lilly USA and chief... 
From PR Newswire
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
CHMP has completed a review of available data for both antibodies for the treatment of confirmed COVID-19 
From PR Newswire
Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data from the pirtobrutinib (previously referred to as... 
From PR Newswire
Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
Trial participants taking the highest dose of tirzepatide (15 mg) achieved an A1C reduction of 2.46 percent and weight loss of 12.4 kg (27.3 lb., 13.1 percent), double the weight reduction compared to... 
From PR Newswire
Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial
- Baricitinib met primary endpoint of hair regrowth across both dosing regimens 
From PR Newswire
U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
90 91 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.